TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
PMN

ProMIS Neurosciences Inc.

Healthcare · Biotechnology

9.40$ +0.2% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Income Statement PMN
Line item 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– 2.43 21.92 16.85 6.29 37.22 2.80 1.45 1.29 8.52 0.28 0.02 0.07 0.00 0.01 0.01 0.07 0.03 0.00 0.00 0.00
– – – – – – – 46.86 – 27.31 14.73 16.47 27.00 – 27.34 16.72 25.28 0.05 21.24 – 18.99
– 2.43 10.39 7.03 6.29 37.22 2.80 -45.41 1.29 -18.79 -14.45 0.02 0.06 0.00 -27.33 -16.71 -25.25 -0.05 -21.24 – -18.99
9.55 73.36 139.50 220.20 116.77 113.70 99.85 59.77 46.72 31.52 10.61 12.25 22.96 34.11 27.34 16.72 21.39 53,605.31 16.03 10.05 19.00
– – – – – – 0.02 14.18 12.59 22.21 9.48 10.35 11.95 12.70 15.12 12.84 14.32 24,300.72 15.03 5.85 3.86
23.32 133.41 351.85 155.12 176.52 142.22 143.17 68.87 59.31 19.53 14.68 22.61 34.91 46.81 42.71 13.03 20.02 77,906.03 17.19 15.90 22.86
-23.32 -99.02 -357.91 -216.24 -165.26 -104.64 -0.08 -65.37 -53.89 -52.96 -29.13 -22.59 -43.83 -46.81 -70.04 -29.74 -45.66 -77,906.03 -38.43 -15.90 -22.86
0.18 0.13 173.34 253.72 6.92 4.13 1.44 0.40 0.06 – 0.33 0.14 0.04 0.00 0.00 0.00 1.80 939.89 0.41 0.07 0.00
-23.50 -127.98 -335.62 -206.44 -160.82 -95.94 -0.08 -65.30 -57.96 -71.52 -29.46 -22.69 -43.88 -46.81 -42.70 -29.74 -53.92 -60,186.68 -35.60 2.63 -22.61
– 131.10 173.34 253.72 145.66 149.80 105.34 74.63 -0.06 0.00 0.24 0.10 0.04 -0.98 0.00 0.00 1.79 -17.72 -0.34 – –
-23.50 -127.98 -335.62 -206.44 -160.82 -95.94 -78.38 -66.28 -53.89 -50.41 -21.23 -22.69 -34.90 -46.81 -42.70 -29.74 -51.76 -60,186.68 -35.60 2.63 -22.61
-23.32 -98.25 -350.06 -141.61 -160.05 -98.32 -76.46 -67.40 -53.50 -71.21 -20.92 -22.55 -34.82 -46.78 -42.65 -29.66 -40.31 -59,246.79 -36.22 2.70 -22.61

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?